Syneron Announces US and Canada Launch of CO2RE System Following FDA and Health Canada Clearance for the System

By Syneron Medical Ltd., PRNE
Monday, November 29, 2010

New fractional CO2 resurfacing laser offers practitioners broader and highly effective treatment options

YOKNEAM, Israel and IRVINE, California, November 30, 2010 - Syneron Medical Ltd. (Nasdaq: ELOS),, the global
leader in the medical aesthetic device marketplace, announced today the US
Food and Drug Administration (FDA) and Health Canada clearance and commercial
launch of its highly flexible CO2RE CO2 resurfacing system. CO2RE is a
versatile fractional CO2 system that offers the unique ability to treat both
superficial and deep skin layers simultaneously with precision-control over
the intensity, pattern and depth of ablation. This patent-pending technology
is the first to receive FDA clearance for all of its operating modes,
including the four major fractional treatment modes. The system can be used
for fractional CO2 resurfacing and traditional ablation, and is ideal for
skin rejuvenation, wrinkle reduction, scar reduction and other aesthetic

"We received very positive physician feedback during the international
roll-out of the CO2RE system and we are excited to begin offering it in the
United States
and Canada, giving our customers more choices and greater
flexibility to meet their individual practice needs. With the addition of
CO2RE, we now offer a complete range of product solutions that address
physicians' and patients' needs across a wide range of facial rejuvenation
treatment categories," said Louis P. Scafuri, Chief Executive Officer of
Syneron. Mr. Scafuri added, "The launch of CO2RE shows the strength of our
globalized approach to research and development. The product was developed by
Inlight Inc., San-Diego, Calif. which was acquired by Syneron at the end of
2008. Inlight brought to Syneron the most advanced scanner and ablative laser
technology which, in combination with Syneron's know-how in light tissue
interaction, enabled us to bring to the market the most advanced and
versatile system for a wide range of ablative skin rejuvenation procedures."

"We've been very happy with the results that we've seen using CO2RE. It
has a lot of versatility and we find it works well for both fractionated
ablative resurfacing as well as traditional ablative resurfacing," said Brian
, MD, a board certified dermatologist at the Zel Skin and Laser

E. Victor Ross, MD, at the Scripps Clinic Carmel Valley Laser and
Cosmetic Dermatology commented, "One of CO2RE's advantages is the handpiece,
which is very easy to hold. In comparison to other fractional handpieces the
CO2RE handpiece is thin, lightweight and easy to maneuver around the skin
during treatments."

About CO2RE

The new CO2RE fractional CO2 resurfacing system is a lighter, faster and
more versatile solution for skin resurfacing, wrinkle and scar reduction, and
other traditional CO2 applications. CO2RE is the only CO2 laser to offer
multi-depth pulse technology, delivering precisely fractionated beam patterns
to treat multiple layers of the epidermis and dermis simultaneously.

About Syneron Medical Ltd.

Syneron Medical Ltd. - a company devoted to real technology, real science
and real results - is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced solutions for a
broad range of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells its products
under two distinct brands, Syneron and Candela. With its innovative approach
to aesthetic treatments, Syneron has now entered into one of the largest
in-demand applications, skin lightening. Founded in 2000, the corporate, R&D
and manufacturing headquarters for Syneron Medical Ltd. are located in
Israel. Syneron also has R&D and manufacturing operations in the US. The
company markets and services and supports its products in 86 countries. It
has offices in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at


Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including
the risk that the businesses of Syneron and Candela may not be integrated
successfully; the risk that the merger transaction with Candela may involve
unexpected costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to realize
than expected; the risk that disruptions from the merger transaction make it
more difficult to maintain relationships with customers, employees, or
suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most
recent Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to time. If
one or more of these factors materialize, or if any underlying assumptions
prove incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results, performance or
achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.


    Asaf Alperovitz, Chief Financial Officer

    Nick Laudico/Zack Kubow, The Ruth Group
    Email: /

Asaf Alperovitz, Chief Financial Officer, + 972-73-244-2283, asafa at, Nick Laudico, +1-646-536-7030, nlaudico at, or Zack Kubow, +1-646-536-7020, zkubow at, both of The Ruth Group

will not be displayed